GMDP Academy is honored to announce that Dr. Xavier Luria has been appointed Chair of the GMDP Academy Board of Officers, joined by Dr. Roslyn (Roz) Schneider as Co-Chair. These visionary leaders bring decades of strategic, regulatory, clinical, and patient-centered expertise that will guide the Academy into its next chapter of growth and impact.

Dr. Luria is a renowned leader in global regulatory science, having served as Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) from 2005 to 2012. With more than 18 years of industry experience in international clinical development, pharmacovigilance, and medical affairs, he is a recognized authority in benefit-risk assessment, regulatory systems, and modeling methodologies. He founded Drug Development and Regulation (DDR) in 2013, a regulatory consultancy based in Barcelona, Amsterdam, and London, which was acquired by Veristat in 2022. He was also a founder of EMA Solutions, a joint venture between DDR and Kinesys Consulting in the UK. In addition, he serves as Expert Consultant at NDA Partners LLC in the USA. Dr. Luria is a Senior Visiting Lecturer at King’s College London and teaches at several academic institutions across Europe and the United States. He serves on advisory boards of biopharmaceutical and medical device companies globally, offering consultancy and regulatory services across Europe, Japan, the US, Australia, Israel, and Latin America.

Dr. Schneider brings a unique perspective grounded in clinical medicine and the pioneering application of human-centered design in life sciences. A board-certified physician in Internal Medicine, Pulmonary, and Critical Care, she spent the first half of her career in hospital leadership and academia before spearheading industry transformation. At Pfizer, she founded the office of Global Patient Affairs, embedding patient partnership principles into R&D processes, which she carried through leadership roles at Theravance, BioMarin, and consulting. Roz currently serves on multiple advisory boards and was awarded a Global Fellowship in Medicines Development by the GMDP Academy in 2023, among numerous other accolades.

Under the leadership of Dr. Luria and Dr. Schneider, the GMDP Academy Board will continue to strengthen its mission of advancing education, standards, and professional development for the global medicines development workforce—helping to shape a future where innovation and inclusivity drive better business outcomes worldwide.

Disclaimers

  • The material in these reviews is from various public open access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred